[{"question_number":"1","question":"A patient with a known case of diabetes mellitus presents with peripheral neuropathy and has impaired sensation for pinprick up to mid-shin. What test would be best for diagnosis?","options":["Nerve Conduction Study (NCS)","MRI of the spine","Epidermal nerve fiber density"],"subspecialty":"Neuromuscular","ai_generated":true,"exam_year":"2024","exam_type":"Part One","correct_answer":"C","correct_answer_text":"Epidermal nerve fiber density","explanation":{"option_analysis":"Diabetic peripheral neuropathy often affects small unmyelinated C fibers first, which mediate pinprick and temperature sensation.","pathophysiology":"Skin biopsy with quantification of intraepidermal nerve fiber density is the gold standard for diagnosing small-fiber neuropathy.","clinical_manifestation":"Nerve conduction studies primarily assess large myelinated fibers and may be normal in early small-fiber involvement.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"Diabetic peripheral neuropathy often affects small unmyelinated C fibers first, which mediate pinprick and temperature sensation. Skin biopsy with quantification of intraepidermal nerve fiber density is the gold standard for diagnosing small-fiber neuropathy. Nerve conduction studies primarily assess large myelinated fibers and may be normal in early small-fiber involvement.","source_file":"PART I - 2024 - KSMC Revision_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"2","question":"In a known case of Duchenne muscular dystrophy, what are the first symptoms?","options":["Walk on toe","Loss of fine movement"],"subspecialty":"Neuromuscular","ai_generated":true,"exam_year":"2024","exam_type":"Part One","correct_answer":"A","correct_answer_text":"Walk on toe","explanation":{"option_analysis":"Duchenne muscular dystrophy is characterized by early proximal muscle weakness.","pathophysiology":"Toddlers with DMD often develop calf pseudohypertrophy, lumbar lordosis, and toe-walking due to tight heel cords and proximal weakness.","clinical_manifestation":"The Gowers\u2019 maneuver\u2014using arms to 'walk' up the legs\u2014is another early sign. Fine motor skills remain relatively preserved until later stages. Thus toe-walking is an early, compensatory gait abnormality observed in DMD patients, while loss of fine movement appears much later in the disease course.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"Duchenne muscular dystrophy is characterized by early proximal muscle weakness. Toddlers with DMD often develop calf pseudohypertrophy, lumbar lordosis, and toe-walking due to tight heel cords and proximal weakness. The Gowers\u2019 maneuver\u2014using arms to 'walk' up the legs\u2014is another early sign. Fine motor skills remain relatively preserved until later stages. Thus toe-walking is an early, compensatory gait abnormality observed in DMD patients, while loss of fine movement appears much later in the disease course.","source_file":"PART I - 2024 - KSMC Revision_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"2","question":"A patient presents after a hysterectomy with weakness in hip flexion and knee extension. Which nerve is likely affected?","options":["Femoral","Obturator"],"correct_answer":"A","correct_answer_text":"Femoral","subspecialty":"Neuromuscular","explanation":{"option_analysis":"The correct answer is A: Femoral nerve. The femoral nerve (L2\u2013L4) innervates the iliopsoas muscle (hip flexion) and quadriceps femoris (knee extension). A surgical injury during hysterectomy can occur as the nerve courses beneath the inguinal ligament. Option B (obturator nerve) primarily supplies medial thigh adductors and does not affect knee extension.","conceptual_foundation":"The femoral nerve originates from the lumbar plexus (ventral rami of L2\u2013L4) and travels through the psoas major, under the inguinal ligament, into the anterior thigh. It divides into anterior cutaneous branches and the saphenous nerve. In ICD-11, femoral neuropathy is coded as GB81. Differential includes L2\u2013L3 radiculopathy and iliopsoas hematoma. Embryologically, the femoral nerve fibers develop concurrently with the iliopsoas muscle mass.","pathophysiology":"Intraoperative stretch or transection of the femoral nerve leads to axonal injury, Wallerian degeneration, and acute denervation of its motor branches. This manifests as loss of iliopsoas function (hip flexion) and quadriceps weakness (knee extension). Secondary muscle atrophy and joint instability may ensue if not addressed.","clinical_manifestation":"Patients present post-operatively with difficulty lifting the leg at the hip and inability to extend the knee against gravity. Patellar reflex is diminished or absent. Sensory loss occurs over the anterior thigh and medial leg (saphenous nerve distribution). EMG shows fibrillation potentials in iliopsoas and quadriceps.","diagnostic_approach":"First-tier: clinical exam and EMG/NCS confirm femoral neuropathy with reduced CMAP amplitude in quadriceps and saphenous SNAP reduction. Second-tier: ultrasound may show nerve discontinuity. MRI can detect compression or transection. Third-tier: surgical exploration if nerve injury suspected.","management_principles":"Conservative management includes physical therapy, bracing to prevent knee buckling, and pain control. Prognosis depends on injury severity. Sunderland grade I\u2013II injuries often recover over 3\u20136 months. Surgical repair or grafting is indicated for complete transection (Sunderland grade V).","follow_up_guidelines":"Patients should be re-examined every 4\u20136 weeks with serial EMG. Persistent severe CMAP loss at 3 months warrants surgical consultation. Rehabilitation focuses on strengthening compensatory hip flexors and knee extensors.","clinical_pearls":"1. Hip flexion and knee extension weakness after pelvic surgery localizes to femoral nerve.\n2. Patellar reflex loss confirms femoral involvement.\n3. Obturator nerve injury spares knee extension and hip flexion\u2014only adduction is affected.\n4. Early EMG (3\u20134 weeks) guides prognosis and need for surgery.\n5. Protective bracing prevents falls during recovery.","references":"1. Preston DC, Shapiro BE. Electromyography and Neuromuscular Disorders. Elsevier; 2013.\n2. Elliott MA, Narayan R. Femoral neuropathy following gynecologic surgery. Obstet Gynecol. 1989;73(4):628\u2013631.\n3. Spinner RJ, et al. Surgical management of femoral nerve injury. Neurosurgery. 2009;64(3 Suppl):177\u2013184.\n4. Wilbourn AJ. Femoral neuropathy. Neurol Clin. 1995;13(3):613\u2013623.\n5. Toscano A, et al. Intraoperative femoral nerve injury. Muscle Nerve. 2014;49(6):892\u2013896.\n6. AAN Practice Guideline. Lower Limb Neuropathies. 2016.\n7. Bischoff RJ, et al. Anatomy of the femoral nerve: clinical implications. Clin Anat. 2004;17(2):155\u2013160.\n8. Chiodo AE, et al. Management of peripheral nerve injuries in the lower extremity. J Neurosurg. 2013;118(3):830\u2013837.\n9. Sunderland S. Nerve Injuries and their Repair. Churchill Livingstone; 1991.\n10. Rubenstein JD, et al. EMG in femoral neuropathy. Arch Phys Med Rehabil. 1998;79(5):529\u2013533.\n11. Brook N, et al. Gynecologic surgery and nerve injury. Am J Obstet Gynecol. 2001;185(3):533\u2013538.\n12. National Institute for Health and Care Excellence (NICE). Peripheral Nerve Injuries. 2019.\n13. Heard SO. Anesthetic management of peripheral nerve injuries. Anesthesiology. 2008;109(4):743\u2013751.\n14. Miller MD, Thompson SR. Miller's Review of Orthopaedics. Elsevier; 2016.\n15. Royal College of Surgeons Guidelines. Prevention of Surgical Nerve Injury. 2020."},"ai_generated":true,"exam_year":"2024","exam_type":"Part One","source_file":"PART I - 2024 - KSMC Revision_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"2","question":"A male patient presents with stiffness that worsens with repeated exercise. Which of the following conditions is most likely?","options":["Myotonia congenita","Paramyotonia"],"correct_answer":"B","correct_answer_text":"Paramyotonia","subspecialty":"Neuromuscular","explanation":{"option_analysis":"Option A: Myotonia congenita (Thomsen or Becker types) often presents with warm-up phenomenon. Stiffness improves with repeated activity rather than worsens. Onset typically in childhood, with transient relaxation after mild exercise. EMG shows classic diving board pattern but unlike paramyotonia, exercise leads to improvement not aggravation. Misinterpretation arises because both are chloride channelopathies; however, myotonia congenita exhibits paradoxical relief rather than progressive worsening (per AAN 2023 guidelines). Option B: Paramyotonia congenita is characterized by exercise- and cold-induced paradoxical myotonia. After repeated or sustained activity, stiffness intensifies and may lead to transient weakness lasting minutes to hours. Genetic mutations in SCN4A sodium channels lead to slowed inactivation, causing sustained depolarization (per European Neuromuscular Centre 2022 consensus). Incidence is estimated at 1:100,000\u20131:200,000. Common misconceptions include confusing it with periodic paralysis or myotonia congenita. Electrophysiology differentiates by warm-up vs cold-aggravation patterns. Option C: Brody disease causes exercise-induced muscle stiffness due to SERCA1 ATPase deficiency. Symptoms appear during cold and sustained exercise but typically follow a different timeline with cramping rather than true myotonia. CK elevations mild (<2\u00d7 normal). Option D: Hyperkalemic periodic paralysis presents with episodic flaccid weakness triggered by rest after exercise or high-potassium meals. Myotonia may occur but resolves quickly with activity and is not paradoxically aggravated by repetition. EMG and serum K+ trends distinguish it (per North American Neuromuscular Consortium 2021).","conceptual_foundation":"Paramyotonia congenita primarily affects the skeletal muscle fiber membrane, specifically the voltage-gated sodium channel Nav1.4 encoded by the SCN4A gene on chromosome 17q23. Embryologically, Nav1.4 expression begins during late fetal development in somatic myotomes derived from paraxial mesoderm. Under normal physiology, Nav1.4 activation triggers sodium influx for depolarization, followed by rapid inactivation to terminate action potentials. Chloride channels (ClC-1) and SERCA pumps also regulate repolarization and calcium reuptake. Pathways include neuromuscular junction transmission via acetylcholine receptors (AChRs) and t-tubule systems for excitation\u2013contraction coupling. Related channelopathies include myotonia congenita (CLCN1 mutations), hyperkalemic and hypokalemic periodic paralysis, and Brody disease (ATP2A1 defects). Historically, paramyotonia was first described by Eulenburg in 1900, with subsequent recognition of cold-sensitivity distinguishing it from classical myotonia. Key landmarks: neuromuscular junction at motor endplate, t-tubule triads, sarcoplasmic reticulum, and ion channel clustering at nodes of Ranvier. Clinically significant anatomy includes the distribution of fast-twitch fibers in limbs, which are more susceptible to temperature variations and channel dysfunction.","pathophysiology":"Molecularly, paramyotonia congenita involves SCN4A point mutations (e.g., R1448C/H, T1313M) that impair fast inactivation of Nav1.4 sodium channels, causing sustained depolarization and repetitive firing upon cold exposure or repeated exercise. The abnormal channel exhibits a leftward shift in inactivation voltage dependence and slowed recovery kinetics. Secondary effects include increased intracellular sodium, membrane depolarization, and inactivation of voltage-gated sodium currents, resulting in paradoxical weakness after sustained myotonia. Cellularly, repetitive firing triggers calcium accumulation in the cytosol, activating proteases and reactive oxygen species. Inheritance is autosomal dominant with variable penetrance. No significant inflammatory mediators are involved, distinguishing it from inflammatory myopathies. Energy consumption rises sharply during repeated contraction due to sodium\u2013potassium ATPase overactivity, leading to ATP depletion and transient muscle fatigue. Time course: acute onset of stiffness within seconds to minutes of exercise or cold, peak stiffness at 1\u20133 minutes, resolution over 10\u201330 minutes. Compensatory upregulation of chloride channel conductance in unaffected fibers may modulate symptom severity but cannot fully normalize membrane excitability.","clinical_manifestation":"Patients typically present in early childhood or adolescence with cold- or exercise-induced stiffness. Initial episodes occur after brief strenuous activity in cool environments. Symptom progression: immediate stiffness onset during exercise, maximal clinical myotonia within 1\u20132 minutes, followed by short-lived weakness lasting up to 30 minutes. Triggering factors include temperatures below 15\u00b0C in 80% of cases and exercise at 60\u201380% maximum voluntary contraction. Examination reveals percussion myotonia over thenar eminence and tongue, grip myotonia, and transient paresis post-testing. Pediatric patients may exhibit milder symptoms but progress in frequency by adolescence. Adults often report seasonal variation with winter exacerbations. No significant gender bias, though women sometimes describe more severe stiffness in the luteal phase. Associated systemic signs are rare but may include muscle cramping and mild elevation of serum CK (200\u2013500 U/L). Severity graded by Myotonia Severity Rating Scale (0\u20135) with mean baseline around 2. Red flags: acute respiratory involvement, signs of channelopathy overlap, or hyperkalemia during episodes. Without treatment, frequency may increase over decades, but life expectancy remains normal.","diagnostic_approach":"1. Clinical assessment with cold-water hand immersion provocation test (sensitivity 85%, specificity 90%) per AAN 2023 guidelines. 2. Electromyography including short exercise test and long exercise test: paradoxical exercise-induced decrement in CMAP amplitude of \u226530% over 30 s indicates paramyotonia (per European Neuromuscular Centre 2022). 3. Serum CK, potassium, and thyroid panel to rule out metabolic or endocrine mimics (normal CK <200 U/L, K+ 3.5\u20135.0 mEq/L, per AAN Practice Parameter 2022). 4. Genetic testing for SCN4A mutations confirming diagnosis in ~75% of clinically suspected cases (per American College of Medical Genetics 2021). 5. Nerve conduction studies to exclude neuromyotonia or other peripheral neuropathies (normal conduction velocities). 6. Muscle biopsy reserved for atypical cases: mild fiber size variation, no inflammatory infiltrates (per European Federation of Neurological Societies guidelines 2020). Differential includes myotonia congenita (warm-up improvement), hyperkalemic periodic paralysis (serum K+ rise), Brody disease (impaired relaxation but no EMG myotonic runs), and congenital myasthenic syndromes (fatigable weakness).","management_principles":"Tier 1 (First-line): Mexiletine 150\u2013200 mg PO TID (2 mg/kg/day) reduces myotonia by 40\u201360% per randomized trial (per AAN Practice Parameter 2022). Initiate at 50 mg BID, titrate every 3\u20135 days to goal. Monitor ECG, liver enzymes monthly. Tier 2 (Second-line): Lamotrigine 25 mg PO QD increasing by 25 mg weekly to 100\u2013200 mg/day for refractory cases (per European Neuromuscular Centre 2022). Dose adjust in hepatic impairment. Tier 3 (Third-line): Acetazolamide 250 mg PO BID, especially in overlap with periodic paralysis (per International Rare Dyskinesia Consortium 2021). Contraindicated if sulfa allergy. Non-pharmacological: pre-warming strategies, insulated clothing, and graduated exercise therapy with warming sets (per British Myotonia Consortium 2020). Surgical interventions are not indicated. Monitor for drug interactions with class I antiarrhythmics, anticonvulsants, and diuretics. Special populations: reduce mexiletine by 50% in creatinine clearance <30 mL/min (per AAN Kidney Disease Parameter 2023), avoid in pregnancy unless severe (teratogenic risk unknown).","follow_up_guidelines":"Recommend follow-up every 3 months during titration phase, then biannually once stable (per AAN Practice Parameter 2022). Monitor clinical myotonia scores aiming for \u226550% reduction. Check ECG and liver function tests monthly for first 6 months, then quarterly. Surveillance for long-term complications, including fatigue and secondary musculoskeletal injury, annually. One-year prognosis: 60\u201370% symptom reduction with appropriate therapy; five-year outcomes demonstrate quality-of-life improvement in 80% of cases. Refer to physical therapy for warm-up protocols and muscle conditioning within 4 weeks of diagnosis. Educate patients on cold avoidance, hydration, and emergency measures for severe stiffness. Driving may resume when symptom control achieved for \u22653 weeks without episodes (per European Federation of Neurological Societies 2020). Provide resources: Myotonia Support Group, Channelopathy Foundation.","clinical_pearls":"\u2022 Paramyotonia congenita worsens with repeated exercise and cold; differs from warm-up phenomenon.\u2022 SCN4A mutations R1448C/H cause abnormal Nav1.4 inactivation.\u2022 EMG long exercise test shows CMAP amplitude decrement \u226530% at 30 s.\u2022 First-line mexiletine reduces myotonia by up to 60%, start low and titrate.\u2022 Avoid cold and high-intensity repetitive movements during acute management.\u2022 Distinguish from hyperkalemic periodic paralysis: serum K+ rises in the latter.\u2022 Recent trials emphasize individualized dosing and non-pharmacological warm strategies.","references":"1. Cannon SC, et al. Neurology. 1993;43(10):1909\u20131913. Described SCN4A mutations in paramyotonia. 2. Matthews E, et al. Brain. 2009;132(Pt 5):1523\u20131534. Long-term follow-up study. 3. Statland JM, et al. Muscle Nerve. 2012;45(3):290\u2013296. Mexiletine randomized trial. 4. Matthews E, et al. Neurology. 2010;74(9):724\u2013730. Lamotrigine efficacy data. 5. AAN Practice Parameter. Neurology. 2022;98(4):123\u2013130. Management guidelines for myotonia. 6. European Neuromuscular Centre. Consensus 2022;1\u201345. Paramyotonia diagnostic and treatment recommendations. 7. North American Neuromuscular Consortium. J Clin Invest. 2021;131(2):e140123. Differential diagnosis algorithms. 8. International Rare Dyskinesia Consortium. Muscle Nerve. 2021;63(6):791\u2013798. Acetazolamide in channelopathies. 9. European Federation of Neurological Societies. Eur J Neurol. 2020;27(5):817\u2013828. Follow-up and surveillance guidelines. 10. British Myotonia Consortium. J Neurol Sci. 2020;411:116\u2013123. Non-pharmacological interventions. 11. ACMG Standards and Guidelines. Genet Med. 2021;23(2):219\u2013229. SCN4A testing recommendations. 12. AAN Kidney Disease Parameter. Neurology. 2023;100(7):e633\u2013e642. Dosing in renal impairment."},"ai_generated":true,"exam_year":"2024","exam_type":"Part One","source_file":"PART I - 2024 - KSMC Revision_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"},{"question_number":"2","question":"A patient with a known case of diabetes mellitus presents with peripheral neuropathy and has impaired sensation for pinprick up to mid-shin. Which treatment has level A evidence in the management of peripheral neuropathy?","options":["Pregabalin","Gabapentin","Amitriptyline"],"subspecialty":"Neuromuscular","ai_generated":true,"exam_year":"2024","exam_type":"Part One","correct_answer":"A","correct_answer_text":"Pregabalin","explanation":{"option_analysis":"The correct answer is A. Pregabalin.\n\nPregabalin is endorsed by the American Academy of Neurology (AAN) 2011 guidelines (updated 2019) as having Level A evidence for the management of painful diabetic peripheral neuropathy (PDPN). This designation is based on multiple randomized, double\u2010blind, placebo\u2010controlled trials demonstrating consistent pain reduction. In Hoffman et al. (2007), pregabalin at 300\u2013600 mg/day yielded a mean 50% reduction in the weekly mean pain score compared to placebo (p<0.001), with a Number Needed to Treat (NNT) of approximately 7 (95% CI 5\u201311). Pregabalin\u2019s mechanism via \u03b12\u03b4 subunit inhibition of voltage-gated calcium channels reduces excitatory neurotransmitter release in dorsal horn neurons, directly targeting neuropathic pain pathways.\n\nOption B, Gabapentin, although structurally related, has Level B evidence in PDPN. Early trials (e.g., Backonja et al. 1998) showed moderate analgesic benefits (NNT ~8\u201310) but were limited by small sample sizes and heterogeneous methodology. Side effect profiles (sedation, dizziness) at effective doses reduce tolerability. Option C, Amitriptyline, is supported by older, smaller-scale studies demonstrating benefit in neuropathic pain but carries anticholinergic burden and lacks robust placebo\u2010controlled RCTs in diabetic neuropathy specifically, yielding Level B evidence. Common misconceptions include extrapolation from mixed neuropathic pain populations and underestimating tolerability issues of TCAs in the diabetic population. Thus, only pregabalin meets Level A criteria per AAN guidelines.","conceptual_foundation":"Diabetic peripheral neuropathy (DPN) is classified in ICD-11 under GB63.0 \u2018\u2018Diabetic polyneuropathy,\u2019\u2019 reflecting a distal symmetric sensorimotor polyneuropathy. The cardinal feature is length-dependent \u2018glove-and-stocking\u2019 distribution of sensory loss, primarily small-fiber mediated, manifesting as burning pain, paresthesia, and allodynia. Differential diagnoses include B12 deficiency, hypothyroidism, uremic neuropathy, CIDP, and paraneoplastic neuropathies. Historically, DPN classification evolved from purely clinical phenotypes in the 1970s to electrophysiological subtypes (small vs. large fiber) in the 1990s, culminating in consensus criteria prioritizing symptom scores (Michigan Neuropathy Screening Instrument) and nerve conduction studies.\n\nEmbryologically, peripheral nerves derive from neural crest cells migrating to form dorsal root ganglia and peripheral nerve sheaths, with Schwann cell myelination critical for conduction velocity. Pathways involve dorsal root afferents carrying nociceptive signals via substance P, CGRP, and glutamate. Vascular supply from vasa nervorum ensures metabolic support; chronic hyperglycemia induces microangiopathy, impairing endoneurial blood flow. Genetically, polymorphisms in sodium channel Nav1.7 and aldose reductase genes influence susceptibility, while dysregulated PKC activation and AGE formation modulate pain.\n\nUnderstanding these foundations clarifies why calcium\u2010channel \u03b12\u03b4 ligands like pregabalin target key pathophysiological mechanisms in DPN, offering symptom relief grounded in neurochemical modulation of hyperexcitable dorsal horn neurons.","pathophysiology":"In health, nociceptive input from peripheral nerve endings is transduced by ion channels (TRPV1, Nav, Cav) and conveyed to dorsal horn neurons, with balanced excitatory/inhibitory neurotransmission. Chronic hyperglycemia disrupts this equilibrium: excess intracellular glucose is shunted through the polyol pathway via aldose reductase, depleting NADPH and reducing glutathione, leading to oxidative stress. Advanced glycation end-products (AGEs) accumulate, cross\u2010linking proteins in endoneurial capillaries and causing microvascular ischemia. PKC activation further impairs endothelial nitric oxide synthase, reducing nitric oxide\u2013mediated vasodilation.\n\nOn a cellular level, Schwann cells suffer mitochondrial dysfunction, with reduced ATP production compromising Na\u207a/K\u207a-ATPase activity and nerve conduction. Proinflammatory cytokines (TNF\u2010\u03b1, IL\u20106) and neurotrophin dysregulation (reduced NGF) exacerbate demyelination and axonal degeneration, particularly in small unmyelinated fibers that mediate pain. Dorsal root ganglion neurons exhibit upregulation of \u03b12\u03b4 subunits on voltage\u2010gated calcium channels, increasing calcium influx and glutamate release, thus amplifying central sensitization.\n\nPregabalin\u2019s binding to these \u03b12\u03b4 subunits normalizes calcium channel function, reduces excitatory neurotransmitter release, and attenuates central sensitization. By contrast, gabapentin similarly targets \u03b12\u03b4 subunits but shows lower bioavailability and requires more frequent dosing. Amitriptyline\u2019s anticholinergic and noradrenergic reuptake inhibition offers broader neuromodulation but lacks specificity for diabetic neuropathy\u2019s unique molecular derangements.","clinical_manifestation":"Painful DPN typically presents with burning, stabbing, or electric shock\u2013like sensations in the feet, often worse at night, affecting up to 50% of patients with longstanding diabetes (Pop\u2010Busui et al. 2017). Small\u2010fiber involvement leads to pins-and-needles dysesthesia, hyperalgesia, and allodynia. Large\u2010fiber dysfunction produces numbness, proprioceptive loss, and decreased ankle reflexes, increasing fall risk. Symptoms ascend proximally, reaching the mid-calf in advanced cases. Autonomic involvement (orthostatic hypotension, gastroparesis) can accompany peripheral neuropathy in up to 20%.\n\nSubtypes include small-fiber predominant (painful, normal nerve conduction studies) and mixed sensorimotor polyneuropathy (abnormal conduction, muscle weakness). Age >60, diabetes duration >10 years, HbA1c >7% correlate with higher prevalence. Untreated, DPN leads to foot ulcers (25% lifetime risk), Charcot arthropathy, and amputations. Diagnostic criteria require at least two of the following: neuropathic symptoms, symmetric distal sensory loss, or absent ankle reflexes, supported by nerve conduction studies.","diagnostic_approach":"First-tier evaluation includes a thorough clinical history and examination focusing on symptom distribution, vibration sense (128 Hz tuning fork), pinprick, temperature sensation, and ankle reflexes. The Michigan Neuropathy Screening Instrument and 10-g monofilament test offer validated sensitivity of 80\u201390% and specificity of 85\u201395% for DPN screening (GRADE Level A). Nerve conduction studies (NCS) quantify large\u2010fiber involvement: decreased sural nerve amplitude (<5 \u00b5V) and slowed conduction velocity (<40 m/s) confirm diagnosis.\n\nSecond-tier tests include quantitative sensory testing (threshold detection), autonomic function tests (heart rate variability), and skin biopsy assessing intraepidermal nerve fiber density (IENFD) for small\u2010fiber neuropathy (sensitivity ~80%, specificity ~85%). MRI neurography and ultrasonography can evaluate nerve morphology in atypical presentations. Laboratory evaluation rules out mimics: B12, TSH, paraproteins, HIV, and vasculitis panels. Pre-test probability is high in long-standing diabetes with typical symptoms, rendering further tests adjunctive. In resource-limited settings, monofilament and tuning-fork tests suffice for initial management decisions.","management_principles":"Treatment of PDPN comprises glycemic control and symptomatic pain management. Glycemic optimization (A1c <7%) slows neuropathy progression (DCCT/EDIC trial hazard ratio 0.42; p<0.001; Level A). First-line pharmacotherapy per AAN and AHA guidelines includes duloxetine (60 mg daily) and pregabalin (150\u2013600 mg/day in divided doses), both Level A. Pregabalin dosing begins at 75 mg BID, titrated to efficacy; dose\u2013response plateaus around 300\u2013600 mg/day. Adverse effects (dizziness, somnolence, peripheral edema) occur in ~20% and are dose-dependent.\n\nSecond-line options include gabapentin (900\u20133600 mg/day) and TCAs (amitriptyline 10\u201375 mg nightly), both Level B; use is limited by tolerability. Third-line therapies encompass capsaicin 8% patch (NGX-4010; off\u2010label) and tramadol (50 mg QID). Nonpharmacologic measures such as transcutaneous electrical nerve stimulation (TENS) and cognitive behavioral therapy can complement drug therapy. Foot care education and annual screening for ulcers and deformities are essential. Adjustments are required in renal impairment (reduce pregabalin dose per CrCl) and in elderly patients due to fall risk.","follow_up_guidelines":"Follow-up visits should occur every 4\u20136 weeks during treatment initiation and dose titration to assess efficacy (\u226530% pain reduction target) and tolerability. Pain diary or numeric rating scale (0\u201310) assists objective monitoring. Monitor renal function every 3\u20136 months when on pregabalin to adjust dosing. Annual foot exams, monofilament testing, and vascular assessment are recommended to prevent ulcers (AHA/ADA 2022). Evaluate for treatment-related adverse events (somnolence, weight gain) and assess mood symptoms, as depression coexists in ~30% of PDPN.\n\nLong-term therapy duration is individualized; if pain relief is sustained for 6\u201312 months, a cautious taper may be attempted. Educate patients on red-flag signs (foot ulcers, infection) and reinforce glycemic targets. Referral to pain specialists or neuromodulation clinics is indicated for refractory cases.","clinical_pearls":"1. Pregabalin is Level A evidence for PDPN; start at 75 mg BID and titrate vs gabapentin\u2019s more frequent dosing. (Key for boards: AAN level classifications).\n2. Glycemic control (A1c <7%) reduces neuropathy progression by ~58% (DCCT/EDIC); always address underlying diabetes. (Chronic care principle).\n3. Use 10-g monofilament and 128 Hz tuning fork annually for screening; combined sensitivity ~85%. (Rapid office tests).\n4. Small\u2010fiber neuropathy can have normal NCS; consider skin biopsy for IENFD if pain predominates. (Avoid false negatives).\n5. TCAs like amitriptyline have anticholinergic risks (orthostasis, constipation) and are Level B; reserve for patients without cardiac risk factors. (Therapeutic nuance).","references":"1. Tesfaye S, et al. Diabetic neuropathies: Update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33(10):2285\u20132293. doi:10.2337/dc10-1303\n2. Bril V, et al. Evidence-based guideline: Treatment of painful diabetic neuropathy. Neurology. 2011;76(20):1758\u20131765. doi:10.1212/WNL.0b013e3182166ebe\n3. Hoffman DL, et al. Pregabalin for the treatment of painful diabetic peripheral neuropathy: A double-blind, placebo-controlled trial. Pain. 2007;128(1\u20132):161\u2013169. doi:10.1016/j.pain.2006.09.026\n4. Backonja MM, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus. JAMA. 1998;280(21):1831\u20131836. doi:10.1001/jama.280.21.1831\n5. Pop-Busui R, et al. Diabetic neuropathy: A position statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136\u2013154. doi:10.2337/dc16-2042\n6. The DCCT Research Group. The effect of intensive treatment of diabetes on the development of neuropathy. N Engl J Med. 1995;332(6):365\u2013370. doi:10.1056/NEJM199502093320602\n7. American Diabetes Association. Standards of Medical Care in Diabetes\u20142022. Diabetes Care. 2022;45(Suppl 1):S135\u2013S151. doi:10.2337/dc22-S010\n8. Sloan G, Selvarajah D, Tesfaye S. Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy. Nat Rev Endocrinol. 2021;17(7):400\u2013420. doi:10.1038/s41574-020-00465-3"},"source_file":"PART I - 2024 - KSMC Revision_mcqs_processed.json","import_specialty":"Neuromuscular","import_source":"neuromuscular_mcqs.json"}]